ripostatin-a and holomycin

A collection of rifampin-resistant mutants of Staphylococcus aureus with characterized RNA polymerase beta-subunit (rpoB) gene mutations was cross-screened against a number of other RNA polymerase inhibitors to correlate susceptibility with specific rpoB genotypes. The rpoB mutants were cross-resistant to streptolydigin and sorangicin A. In contrast, thiolutin, holomycin, corallopyronin A, and ripostatin A retained activity against the rpoB mutants. The second group of inhibitors may be of interest as drug development candidates.

Topics: Anti-Bacterial Agents; Antibiotics, Antitubercular; DNA-Directed RNA Polymerases; Drug Resistance, Microbial; Enzyme Inhibitors; Lactams; Lactones; Microbial Sensitivity Tests; Pyrrolidinones; Rifampin; Staphylococcus aureus